Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

NCT01351935 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01351935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01351935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2011
Completion date
June 26, 2015
Enrollment
113 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

b cell non-hodgkin's lymphoma, chronic lymphocytic leukemia, waldenstrom macroglobulinemia